The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19.
de Leon
Jose
J
D000483:Alleles; D000897:Anti-Ulcer Agents / Q000378:metabolism; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000378:metabolism*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism*; D000069445:Atomoxetine Hydrochloride; D015283:Citalopram / Q000378:metabolism; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D014644:Genetic Variation; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics / Q000378:metabolism*; D009853:Omeprazole / Q000378:metabolism; D010597:Pharmacogenetics; D010641:Phenotype; D011437:Propylamines / Q000378:metabolism; D044469:Racial Groups
D000897:Anti-Ulcer Agents; D000929:Antidepressive Agents, Tricyclic; D011437:Propylamines; D015283:Citalopram; D000069445:Atomoxetine Hydrochloride; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D009853:Omeprazole